LANA2 Antibody (CM-A807) [HRP]

• Reactivity: Hu, Mu, V-Vi
• Applications: WB, ELISA, ICC/IF, IHC, IP, KO
• Clone: CM-A807
• Clonality: Monoclonal
• Host: Mouse
• Conjugate: HRP

LANA2 Antibody (CM-A807) [HRP] Summary

• Immunogen: Recombinant LANA2 fusion protein.
• Localization: Nuclear
• Specificity: This is specific for KSHV LANA2 (residues 143-310 epitope recognition).
• Isotype: IgG1 Kappa
• Clonality: Monoclonal
• Host: Mouse
• Purity: Protein G purified

Applications/Dilutions

• Dilutions:
  • ELISA
  • Immunocytochemistry/ Immunofluorescence
  • Immunohistochemistry
  • Immunohistochemistry-Frozen
  • Immunohistochemistry-Paraffin
  • Immunoprecipitation
  • Knockout Validated
  • Western Blot
• Application Notes: Optimal dilution of this antibody should be experimentally determined.
• Readout System:
  • NovaLume Plus Chemiluminescent Reagent LUM-555

Reactivity Notes

Reacts with viral LANA2 protein and shows no cross-reactivity to cellular proteins. Also reacts with human and mouse viral KSHV proteins.

Packaging, Storage & Formulations

• Storage: Store at 4C in the dark.
• Buffer: PBS
• Preservative: No Preservative
• Purity: Protein G purified

Alternate Names for LANA2 Antibody (CM-A807) [HRP]

• LANA 2
• LANA-2
• Latency-associated nuclear antigen 2
• vIRF 3
• vIRF3
• vIRF-3

Background

LANA2 (latency-associated nuclear antigen) is an inhibitor of p53-induced transcription in reporter assays and may be an apoptosis antagonist. It is a nuclear protein associated with Kaposi's sarcoma-associated herpes virus (KSHV), or human herpes virus 8. It is found in abundance in the nuclei of cultured cells from KSHV-infected hematopoietic tissues, such as PEL (primary effusion lymphoma) and CD (multicentric Castleman's disease). It does not appear to be expressed in KS (Kaposi's sarcoma) lesions.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Publications for LANA2 Antibody (NB200-167H)(2)

Publications using NB200-167H

• Moodad S, El Hajj R, Hleihel R et al Lenalidomide in Combination with Arsenic Trioxide: an Effective Therapy for Primary Effusion Lymphoma Cancers (Basel) 2020-09-05 [PMID: 32883022] (WB, WB)
  
  Details:
  Citation using the HRP version of this antibody.
• Moodad SH VIRALLY-INDUCED HEMATOLOGICAL MALIGNANCIES WITH DISMAL PROGNOSIS: IMPACT OF EPIGENETICS AND POTENTIAL THERAPEUTICS Thesis 2021-01-01 (WB)